|
[1]
|
Phan, P., Saikia, B.B., Sonnaila, S., et al. (2021) The Saga of Endocrine FGFs. Cells, 10, Article No. 2418. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Naugler, E., Tarlow, D., Fedorov, M., et al. (2015) Fibroblast Growth Factor Signaling Controls Liver Size in Mice with Humanized Livers. Gastroenterology, 149, 728-740. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Itoh, N., Ohta, H. and Konishi, M. (2015) Endocrine FGFs: Evolution, Physiology, Pathophysiology, and Pharmacotherapy. Frontiers in Endocrinology, 6, Article No. 154. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Zhang, F., Yu, L., Lin, X., et al. (2015) Minireview: Roles of Fi-broblast Growth Factors 19 and 21 in Metabolic Regulation and Chronic Diseases. Molecular Endocrinology, 29, 1400-1413. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Miyata, M., Hata, T., Yamazoe, Y., et al. (2014) SREBP-2 Negatively Regulates FXR-Dependent Transcription of FGF19 in Human Intestinal Cells. Biochemical and Biophysical Research Communications, 443, 477-482. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Li, J., Witonsky, D., Sprague, E., et al. (2021) Genomic and Epigenomic Active Vitamin D Responses in Human Colonic Organoids. Physiological Genomics, 53, 235-248. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Guthrie, G., Stoll, B., Chacko, S., et al. (2020) Rifam-picin, Not Vitamin E, Suppresses Parenteral Nutrition-Associated Liver Disease Development through the Pregnane X Receptor Pathway in Piglets. American Journal of Physiology—Gastrointestinal and Liver Physiology, 318, G41-G52. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
Wang, L., Frey, M. and Kohli, R. (2021) The Role of FGF19 and MALRD1 in Enterohepatic Bile Acid Signaling. Frontiers in Endocrinology, 12, Article ID: 799648. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Bhat, N., Esteghamat, F., Chaube, K., et al. (2022) TCF7L2 Transcriptionally Regulates Fgf15 to Maintain Bile Acid and Lipid Homeostasis through Gut-Liver Crosstalk. The FASEB Journal, 36, e22185. [Google Scholar] [CrossRef]
|
|
[10]
|
Somm, E. and Jornayvaz, R. (2018) Fibroblast Growth Factor 15/19: From Basic Functions to Therapeutic Perspectives. Endocrine Reviews, 39, 960-989. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Tomiyama, K., Maeda, R., Urakawa, I., et al. (2010) Relevant Use of Klotho in FGF19 Subfamily Signaling System in Vivo. Proceedings of the National Academy of Sciences of the United States of America, 107, 1666-1671. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Kir, S., Beddow, S.A., Samuel, V.T., et al. (2011) FGF19 as a Postprandial, Insulin-Independent Activator of Hepatic Protein and Glycogen Synthesis. Science, 331, 1621-1624. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Kong, B., Wang, L., Chiang, J.Y.L., et al. (2012) Mechanism of Tissue-Specific Farnesoid X Receptor in Suppressing the Expression of Genes in Bile-Acid Synthesis in Mice. Hepatol-ogy, 56, 1034-1043. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Johansson, H., Mörk, L.M., Li, M., et al. (2018) Circulating Fibroblast Growth Factor 19 in Portal and Systemic Blood. Journal of Clinical and Experimental Hepatology, 8, 162-168. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Xu, A.W. (2018) Hypothalamic Sensing of Bile Acids, a Gut Feeling. Trends in Endocrinology & Metabolism, 29, 363-366. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Tang, X., Yang, Q., Yang, F., et al. (2016) Target Profiling Anal-yses of Bile Acids in the Evaluation of Hepatoprotective Effect of Gentiopicroside on ANIT-Induced Cholestatic Liver Injury in Mice. Journal of Ethnopharmacology, 194, 63-71. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Al-Khaifi, A., Rudling, M. and Angelin, B. (2018) An FXR Ago-nist Reduces Bile acid Synthesis Independently of Increases in FGF19 in Healthy Volunteers. Gastroenterology, 155, 1012-1016. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Luo, J., Ko, B., Elliott, M., et al. (2014) A Nontumorigenic Var-iant of FGF19 Treats Cholestatic Liver Diseases. Science Translational Medicine, 6, ra100. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Sanyal, J., Ling, L., Beuers, U., et al. (2021) Potent Suppres-sion of Hydrophobic Bile Acids by Aldafermin, an FGF19 Analogue, across Metabolic and Cholestatic Liver Diseases. JHEP Reports, 3, Article No. 100255. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Potthoff, J., Kliewer, A. and Mangelsdorf, D.J. (2012) Endocrine Fibroblast Growth Factors 15/19 and 21: From Feast to Famine. Genes & Development, 26, 312-324. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Sonne, D.P., Van Nierop, F.S., Kulik, W., et al. (2016) Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients with Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism, 101, 3002-3009. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Zhou, M., Luo, J., Chen, M., et al. (2017) Mouse Species-Specific Control of Hepatocarcinogenesis and Metabolism by FGF19/FGF15. Journal of Hepatology, 66, 1182-1192. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Morton, J., Matsen, E., Bracy, P., et al. (2013) FGF19 Action in the Brain Induces Insulin-Independent Glucose Lowering. Journal of Clinical Investigation, 123, 4799-808. [Google Scholar] [CrossRef]
|
|
[24]
|
Fu, L., John, L.M., Adams, S.H., et al. (2004) Fibroblast Growth Factor 19 Increases Metabolic Rate and Reverses Dietary and Leptin-Deficient Diabetes. Endocrinology, 145, 2594-603. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Potthoff, M.J., Boney-Montoya, J., Choi, M., et al. (2011) FGF15/19 Regulates Hepatic Glucose Metabolism by Inhibiting the CREB-PGC-1α Pathway. Cell Metabolism, 13, 729-738. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Hu, X., Xiong, Q., Xu, Y., et al. (2018) Association of Serum Fi-broblast Growth Factor 19 Levels with Visceral Fat Accumulation Is Independent of Glucose Tolerance Status. Nutrition, Metabolism & Cardiovascular Diseases, 28, 119-125. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Schreuder, C.M.A., Marsman, H.A., Lenicek, M., et al. (2010) The Hepatic Response to FGF19 Is Impaired in Patients with Nonalcoholic Fatty Liver Disease and Insulin Resistance. American Journal of Physiology—Gastrointestinal and Liver Physiology, 298, G440-G445. [Google Scholar] [CrossRef] [PubMed]
|
|
[28]
|
Schumacher, J.D., Kong, B., Pan, Y., et al. (2017) The Effect of Fi-broblast Growth Factor 15 Deficiency on the Development of High Fat Diet Induced Non-Alcoholic Steatohepatitis. Toxicology and Applied Pharmacology, 330, 1-8. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Miyata, M., Sakaida, Y., Matsuzawa, H., et al. (2011) Fibroblast Growth Factor 19 Treatment Ameliorates Disruption of Hepatic Lipid Metabolism in Farnesoid X Receptor (Fxr)-Null Mice. Biological and Pharmaceutical Bulletin, 34, 1885-1889.
|
|
[30]
|
Alvarez-Sola, G., Uriarte, I., Latasa, M.U., et al. (2017) Fibroblast Growth Factor 15/19 (FGF15/19) Protects from Diet-Induced Hepatic Steatosis: Development of an FGF19-Based Chimeric Molecule to Promote Fatty Liver Regeneration. Gut, 66, 1818-1828. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Zhou, M., Learned, R.M., Rossi, S.J., et al. (2017) Engineered FGF19 Eliminates Bile Acid Toxicity and Lipotoxicity Leading to Resolution of Steatohepatitis and Fibrosis in Mice. Hepatology Communications, 1, 1024-1042. [Google Scholar] [CrossRef] [PubMed]
|
|
[32]
|
Uriarte, I., Latasa, M.U., Carotti, S., et al. (2015) Ileal FGF15 Contributes to Fibrosis-Associated Hepatocellular Carcinoma Development. International Journal of Cancer, 136, 2469-2475. [Google Scholar] [CrossRef] [PubMed]
|
|
[33]
|
Harrison, S.A., Rinella, M.E., Abdelmalek, M.F., et al. (2018) NGM282 for Treatment of Non-Alcoholic Steatohepatitis: A Multicentre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet, 391, 1174-1185. [Google Scholar] [CrossRef]
|
|
[34]
|
Harrison, S., Rossi, S., Bashir, M., et al. (2018) NGM282 Improves Fibrosis and NASH-Related Histology in 12 Weeks in Patients with Biopsy-Confirmed NASH, Which Is Preceded by Significant Decreases in Hepatic Steatosis, Liver Transaminases and Fibrosis Markers at 6 Weeks. Journal of Hepatology, 68, S65-S66. [Google Scholar] [CrossRef]
|
|
[35]
|
Harrison, S.A., Neff, G., Guy, C.D., et al. (2021) Efficacy and Safety of Aldafermin, an Engineered FGF19 Analog, in a Randomized, Double-Blind, Placebo-Controlled Trial of Patients with Nonalcoholic Steatohepatitis. Gastroenterology, 160, 219-231.E1. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Lan, T., Morgan, D.A., Rahmouni, K., et al. (2017) FGF19, FGF21, and an FGFR1/β-Klotho-Activating Antibody Act on the Nervous System to Regulate Body Weight and Glyce-mia. Cell Metabolism, 26, 709-718.E3. [Google Scholar] [CrossRef] [PubMed]
|
|
[37]
|
Wu, A.L., Coulter, S., Liddle, C., et al. (2011) FGF19 Regulates Cell Proliferation, Glucose and Bile Acid Metabolism via FGFR4-Dependent and Independent Pathways. PLoS ONE, 6, e17868. [Google Scholar] [CrossRef] [PubMed]
|
|
[38]
|
Sun, Y.N., Yang, Z.X., Ren, F.Z. and Fang, B. (2020) FGF19 Alleviates Palmitate-Induced Atrophy in C2C12 Cells by Inhibiting Mitochondrial Overload and Insulin Resistance. In-ternational Journal of Biological Macromolecules, 158, 401-407. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Guo, A., Li, K. and Xiao, Q. (2020) Fibroblast Growth Factor 19 Alleviates Palmitic Acid-Induced Mitochondrial Dysfunction and Oxidative Stress via the AMPK/PGC-1α Pathway in Skeletal Muscle. Biochemical and Biophysical Research Communications, 526, 1069-1076. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Kong, B., Sun, R., Huang, M., et al. (2018) Fibroblast Growth Factor 15-Dependent and Bile Acid-Independent Promotion of Liver Regeneration in Mice. Hepatology, 68, 1961-1976. [Google Scholar] [CrossRef] [PubMed]
|
|
[41]
|
French, D.M., Lin, B.C., Wang, M.P., et al. (2012) Targeting FGFR4 In-hibits Hepatocellular Carcinoma in Preclinical Mouse Models. PLoS ONE, 7, e36713. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Tan, Q., Li, F., Wang, G., et al. (2016) Identification of FGF19 as a Prognostic Marker and Potential Driver Gene of Lung Squamous Cell Carcinomas in Chinese Smoking Patients. Oncotarget, 7, 18394-402. [Google Scholar] [CrossRef] [PubMed]
|
|
[43]
|
Li, F., Li, Z., Han, Q., et al. (2020) Enhanced Autocrine FGF19/FGFR4 Signaling Drives the Progression of Lung Squamous Cell Carcinoma, Which Responds to mTOR Inhib-itor AZD2104. Oncogene, 39, 3507-3521. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Wu, X., Ge, H., Lemon, B., et al. (2010) Separating Mitogenic and Metabolic Activities of Fibroblast Growth Factor 19 (FGF19). Proceedings of the National Academy of Sciences of the United States of America, 107, 14158-14163. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Benoit, B., Meugnier, E., Castelli, M., et al. (2017) Fibroblast Growth Factor 19 Regulates Skeletal Muscle Mass and Ameliorates Muscle Wasting in Mice. Nature Medicine, 23, 990-996. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Guo, A., Li, K., Tian, H.C., et al. (2021) FGF19 Protects Skeletal Muscle against Obesity-Induced Muscle Atrophy, Metabolic Derangement and Abnormal Irisin Levels via the AMPK/SIRT-1/PGC-α Pathway. Journal of Cellular and Molecular Medicine, 25, 3585-3600. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Itoh, N., Ohta, H., Nakayama, Y. and Konishi, M. (2016) Roles of FGF Signals in Heart Development, Health, and Disease. Frontiers in Cell and Developmental Biology, 4, Article No. 110. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
Maeda, T., Kanzaki, H., Chiba, T., et al. (2019) Serum Fibroblast Growth Factor 19 Serves as a Potential Novel Biomarker for Hepatocellular Carcinoma. BMC Cancer, 19, Article No. 1088. [Google Scholar] [CrossRef] [PubMed]
|